You are here: Industry Insights > Bristol-Myers

News List

Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors fiercepharma
April 02, 2019
Bristol-Myers Squibb has found success with its Opdivo-Yervoy combo in treating various common tumors.
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet fiercepharma
February 24, 2019
Activist hedge fund Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.
Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb's kidney cancer share fiercepharma
February 24, 2019
Bristol-Myers Squibb investors have been dreading positive kidney cancer results from archrival Merck for months. And now that they’re here, they might do even more damage to Bristol-Myers’ market share than some industry watchers expected.
Activist Starboard wants to know if Bristol-Myers investors support Celgene buy fiercepharma
February 24, 2019
It was only a month after Bristol-Myers Squibb kicked off 2019 by announcing it would buy Celgene for $74 billion that rumors emerged about activist hedge fund Starboard Value taking an interest in the deal—and not necessarily a positive one. Now those mu
Bristol-Myers confirms activist Starboard has its shares. And it wants board seats, too fiercepharma
February 24, 2019
When it comes to Bristol-Myers Squibb, the rumors are true. Activist investor Starboard Value has indeed taken a stake in the merger-bound pharma—and it’s looking to meddle further.
Bristol-Myers, Roche will top burgeoning I-O market worth $29B: analyst fiercepharma
January 29, 2019
Bristol-Myers Squibb may be falling behind in the metastatic cancer race, and Roche is dealing with biosimilar attacks on its top-selling drugs.
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data fiercepharma
January 28, 2019
Investors panicked back in October when Bristol-Myers Squibb admitted that a request for additional data from a key lung cancer trial had pushed back an FDA decision. And perhaps rightly so.
The skeptics were right: Bristol-Myers has pulled a crucial Opdivo lung filing as it awaits more data fiercepharma
January 28, 2019
Investors panicked back in October when Bristol-Myers Squibb admitted that a request for additional data from a key lung cancer trial had pushed back an FDA decision. And perhaps rightly so.
Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal fiercepharma
January 09, 2019
Bristol-Myers Squibb and Celgene sent 2019's first big shockwave throughout pharma with last week's $74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on t
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal fiercepharma
January 08, 2019
It’s not only Celgene investors who are set for a big payoff with this week’s $74 billion sale to Bristol-Myers Squibb. Thanks to brand-new severance agreements inked days ahead of the deal announcement, its top executives could reap hefty gains, too.

Previous page 1 2 3 4 5 Next page